Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of lifr or fgfr3 as a cell surface marker for isolating human cardiac ventricular progenitor cells

a cell surface marker and progenitor cell technology, applied in 3d culture, skeletal/connective tissue cells, instruments, etc., can solve the problems of unsuitable for isolating large quantities of viable cells, unmet clinical needs, etc., to enhance ventricular function, improve function in a damaged heart, and easy and rapid cell isolation

Pending Publication Date: 2020-08-27
PROCELLA THERAPEUTICS AB
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patent describes a new method for isolating and culturing human cardiac progenitor cells that can differentiate into ventricular muscle cells. These cells can be used to improve heart function in patients with damage to the ventricular region. The method involves using specific markers, such as LIFR and FGFR3, to identify and isolate the progenitor cells. The cells can be expanded to large numbers in the laboratory and can be transplantated into the heart to regenerate damaged tissue. The patent also describes a new method for culturing the cells in a way that allows them to differentiate into ventricular muscle cells. Overall, this patent provides a way to prepare and use human cardiac progenitor cells for therapeutic purposes and to study the development and differentiation of ventricular muscle cells.

Problems solved by technology

Although heart transplantation can be curative, the markedly limited availability of human heart organ donors has led to a widespread unmet clinical need for a renewable source of pure, mature and functional human ventricular muscle tissue (Segers, V. F. M. and Lee, R. J. (2008) Nature 451:937-942; Später, D. et al.
While human pluripotent stem cells hold great promise, a significant challenge has been the ability to move from simply differentiation of diverse cardiac cells to forming a larger scale pure 3D ventricular muscle tissue in vivo, which ultimately requires vascularization, assembly and alignment of an extracellular matrix, and maturation.
While the identification of Isl1 as a marker of cardiac progenitor cells was a significant advance, since Isl1 is an intracellular protein it is not a suitable marker for use in isolating large quantities of viable cells.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of lifr or fgfr3 as a cell surface marker for isolating human cardiac ventricular progenitor cells
  • Use of lifr or fgfr3 as a cell surface marker for isolating human cardiac ventricular progenitor cells
  • Use of lifr or fgfr3 as a cell surface marker for isolating human cardiac ventricular progenitor cells

Examples

Experimental program
Comparison scheme
Effect test

example 1

n of Human Isl1+ Cardiomyogenic Progenitor Cells by Modulation of Wnt Signaling in Human Pluripotent Stem Cells

[0207]Temporal modulation of canonical Wnt signaling has been shown to be sufficient to generate functional cardiomyocytes at high yield and purity from numerous hPSC lines (Lian, X. et al. (2012) Proc. Natl. Acad. Sci. USA 109:E1848-1857; Lian, X. et al. (2013) Nat. Protoc. 8:162-175). In this approach, Wnt / β-catenin signaling first is activated in the hPSCs, followed by an incubation period, followed by inhibition of Wnt / β-catenin signaling. In the originally published protocol, Wnt / β-catenin signaling activation was achieved by incubation with the Gsk3 inhibitor CHIR99021 (GSK-3 α, IC50=10 nM; GSK-3, β IC50=6.7 nM) and Wnt / β-catenin signaling inhibition was achieved by incubation with the Porcn inhibitor IWP2 (IC50=27 nM). Because we used Gsk3 inhibitor and Wnt production inhibitor for cardiac differentiation, this protocol was termed GiWi protocol. To improve the effici...

example 2

ation of Jagged 1 as a Cell Surface Marker of Cardiac Progenitor Cells

[0215]To profile the transcriptional changes that occur during the cardiac differentiation process at a genome-scale level, RNA sequencing (RNA-seq) was performed at different time points following differentiation to build cardiac development transcriptional landscapes. We performed RNA-seq experiments on day 0 to day 7 samples, as well as day 19 and day 35 samples (two independent biological replicates per time point). Two batches of RNA-seq (100 bp and 50 bp read length) were performed using the illumine Hiseq 2000 platform. In total, 20 samples were examined. Bowtie and Tophat were used to map our reads into a reference human genome (hg19) and we calculate each gene expression (annotation of the genes according to Refseq) using RPKM method (Reads per kilobase transcript per million reads). Differentiation of hPSCs to cardiomyocytes involves five major cell types: pluripotent stem cells (day 0), mesoderm progeni...

example 3

fferentiation of Isl1+Jag1+ Cardiac Progenitor Cells

[0224]To characterize the clonal differentiation potential of Isl1+Jag1+ cells, cardiomyogenic progenitor cells were generated by the culturing protocol described in Example 1, and one single Isl1+Jag1+ cell was seeded into one well of a Matrigel-coated 48-well plate. Cells were purified with antibody of Jag1 and then one single cell was seeded into one well. The single cells were then cultured for 3 weeks in Cardiac Progenitor Culture (CPC) medium (advanced DMEM / F12 supplemented with 2.5 mM GlutaMAX, 100 μg / ml Vitamin C, 20% Knockout Serum Replacement).

[0225]Immunostaining of the 3-week differentiation cell population was then performed with three antibodies: cardiac troponin 1 (cTn1) for cardiomyocytes, CD144 (VE-cadherin) for endothelial cells and smooth muscle actin (SMA) for smooth muscle cells. The results showed that the single cell-cultured, Isl1+Jag1+ cells gave rise to cTn1 positive and SMA positive cells, but not VE-cadh...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides LIFR and FGFR3 as cell surface markers for isolating human cardiomyogenic ventricular progenitor cells, in particular progenitor cells that preferentially differentiate into cardiac ventricular muscle cells. Thus, the invention provides human ventricular progenitor (HVP) cells. The invention provides in vitro methods of the separation of Islet 1+ LIFR+ ventricular progenitor cells and / or Islet 1+ / FGFR3+ ventricular progenitor cells and / or Islet 1+ / LIFR+ / FGFR3+ ventricular progenitor cells, and the large scale expansion and propagation thereof. Large clonal populations of isolated LIFR+ and / or FGFR3+ ventricular progenitor cells are also provided. Methods of in vivo use of LIFR+ and / or FGFR3+ ventricular progenitor cells for cardiac repair or to improve cardiac function are also provided. Methods of using the LIFR+ and / or FGFR3+ ventricular progenitor cells for cardiac toxicity screening of test compounds are also provided.

Description

RELATED APPLICATIONS[0001]This application is a continuation of U.S. Ser. No. 14 / 984,783, filed on Dec. 30, 2015, which is a continuation in part of U.S. Ser. No. 14 / 832,324, filed on Aug. 21, 2015, which claims the benefit of the priority date of U.S. Provisional Application No. 62 / 040,892, filed on Aug. 22, 2014, and U.S. Provisional Application No. 62 / 194,016, filed on Jul. 17, 2015. The content of these applications is hereby incorporated by reference in its entirety.BACKGROUND OF THE INVENTION[0002]Heart failure, predominantly caused by myocardial infarction, is the leading cause of death in both adults and children worldwide and is increasing exponentially worldwide (Bui, A. L. et al. (2011) Nat. Rev. Cardiol. 8:30-41). The disease is primarily driven by the loss of ventricular muscle that occurs during myocardial injury (Lin, Z. and Pu, W. T. (2014) Sci. Transl. Med. 6:239rv1) and is compounded by the negligible ability of the adult heart to mount a regenerative response (Ber...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K35/34G01N33/50C12N5/077
CPCC12N5/0657A61K35/34C12N2506/45C12N2501/119C12N2506/02C12N2501/415G01N33/5014C12N2513/00C12N2501/42C12N2501/235
Inventor CHIEN, KENNETH R.LIAN, XIAOJUN LANCE
Owner PROCELLA THERAPEUTICS AB
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com